References
- Fugelstad A, Annell A, Rajs J, Ågren G. Mortality and causes and manner of death among drug addicts in Stockholm during the period 1981–1992. Acta Psychiatr Scand. 1997;96:169–75.doi:https://doi.org/10.1111/j.1600-0447.1997.tb10147.x.
- Coffa D, Snyder H. Opioid use disorder: medical treatment options. Am Fam Physician. 2019;100:416–25.
- Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med. 2005;61:1026–44. doi:https://doi.org/10.1016/j.socscimed.2004.12.024.
- Jin H, Marshall BDL, Degenhardt L, Strang J, Hickman M, Fiellin DA, Ali R, Bruneau J, Larney S. Global opioid agonist treatment: a review of clinical practices by country. Addiction (Abingdon, England). 2020;115:2243–54. doi:https://doi.org/10.1111/add.15087.
- Ridge G, Gossop M, Lintzeris N, Witton J. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. Strang JJJosat. 2009;37:95–100.
- O’Connor P, Oliveto A, Shi J, Triffleman E, Carroll K, Kosten T, Rounsaville B, Pakes J, Schottenfeld R. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105:100–05. doi:https://doi.org/10.1016/S0002-9343(98)00194-6.
- Chen J-S. Harm reduction policy in Taiwan: toward a comprehensive understanding of its making and effects. Harm Reduct J. 2016;13:11. doi:https://doi.org/10.1186/s12954-016-0101-6.
- Lin C-K, Hung -C-C, Peng C-Y, Chao E, Lee TS-HJ. Factors associated with methadone treatment duration: a cox regression analysis. PLoS One. 2015;10:e0123687. doi:https://doi.org/10.1371/journal.pone.0123687.
- Amiri S, Lutz R, Socías ME, McDonell MG, Roll JM, Amram O. Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington. J Subst Abuse Treat. 2018;93:26–30.doi:https://doi.org/10.1016/j.jsat.2018.07.006.
- Amiri S, Lutz RB, McDonell MG, Roll JM, Amram O. Spatial access to opioid treatment program and alcohol and cannabis outlets: analysis of missed doses of methadone during the first, second, and third 90 days of treatment. Am J Drug Alcohol Abuse. 2020;46:78–87.doi:https://doi.org/10.1080/00952990.2019.1620261.
- Wong NS, Lee SS, Lin H. Assessing the spatial distribution of methadone clinic clients and their access to treatment. Harm Reduct J. 2010;7:14. doi:https://doi.org/10.1186/1477-7517-7-14.
- Kelley D, Welch R, McKnelley W. Methadone maintenance: an assessment of potential fluctuations in behavior between doses. Int J Addict. 1978;13:1061–68. doi:https://doi.org/10.3109/10826087809039326.
- Alderks CE Trends in the use of methadone and buprenorphine at substance abuse treatment facilities: 2003 to 2011. In The CBHSQ Report; Rockville (MD): Substance Abuse and Mental Health Services Administration (US), 2013, 1–7.
- Rosenblum A, Cleland CM, Fong C, Kayman DJ, Tempalski B, Parrino M. Distance traveled and cross-state commuting to opioid treatment programs in the United States. J Environ Public Health. 2011;2011:948789.doi:https://doi.org/10.1155/2011/948789.
- Alderks CE Trends in the Use of methadone and buprenorphine at substance abuse treatment facilities: 2003 to 2011. In The CBHSQ Report: Substance Abuse and Mental Health Services Administration (US), 2013.
- Gowing L, Ali R, White JM. Buprenorphine for the management of opioid withdrawal [update of Cochrane Database Syst Rev 2004; 4: CD002025; PMID: 15495026]. Cochrane Database Syst Rev. 2006;2.
- Kimber J, Larney S, Hickman M, Randall D, Degenhardt L. Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry. 2015;2:901–08. doi:https://doi.org/10.1016/S2215-0366(15)00366-1.
- Caplehorn JR, Drummer OH. Mortality associated with New South Wales methadone programs in 1994: lives lost and saved. Med J Aust. 1999;170:104–09.doi:https://doi.org/10.5694/j.1326-5377.1999.tb127675.x.
- Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess (Rockv) (Winchester, England). 2007;11:1–171, iii–iv. doi:https://doi.org/10.3310/hta11090.
- Jackson H, Mandell K, Johnson K, Chatterjee D, Vanness DJ. Cost-effectiveness of injectable extended-release naltrexone compared with methadone maintenance and buprenorphine maintenance treatment for opioid dependence. Subst Abus. 2015;36:226–31. doi:https://doi.org/10.1080/08897077.2015.1010031.
- Barnett PG, Zaric GS, Brandeau MLJ. The cost–effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction. 2001;96:1267–78. doi:https://doi.org/10.1046/j.1360-0443.2001.96912676.x.
- Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction (Abingdon, England). 2009;104:982–92. doi:https://doi.org/10.1111/j.1360-0443.2009.02539.x.
- Billi JE, Pai CW, Spahlinger DA. The effect of distance to primary care physician on health care utilization and disease burden. Health Care Manage Rev. 2007;32:22–29.doi:https://doi.org/10.1097/00004010-200701000-00004.